A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Anemia, Hematology |
| Therapuetic Areas: | Hematology |
| Healthy: | No |
| Age Range: | 12 - Any |
| Updated: | 3/22/2019 |
| Start Date: | May 29, 2009 |
| End Date: | August 31, 2020 |
A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Aplastic Anemia Patients With Immunosuppressive-Therapy Refractory Thrombocytopenia
Severe aplastic anemia (SAA) is a life-threatening blood disease which can be effectively
treated with immunosuppressive drug regimens or allogeneic stem cell transplantation.
However, 20-40% of patients without transplant options do not respond to immunosuppressive
therapies, and have persistent severe cytopenias, requiring regular platelet transfusions,
which are expensive and inconvenient, and are a risk for further serious bleeding
complications.
Thrombopoietin (TPO) is the principal endogenous regulator of platelet production and also
stimulates hematopoietic stem and progenitor cells. A small molecule oral TPO-agonist,
eltrombopag has been shown to increase platelets in healthy subjects and in patients with
immune thrombocytopenic purpura (ITP), and received FDA approval in 2008 for the treatment of
thrombocytopenia in ITP. This Phase 2, non-randomized pilot study of eltrombopag in aplastic
anemia patients with immunosuppressive therapy refractory thrombocytopenia will test the
safety and potential efficacy of eltrombopag treatment patients with refractory
thrombocytopenia following immunosuppression for aplastic anemia.
Subjects will initiate study medication at an oral dose of 50 mg/day, which will be increased
up to 150 mg/day as clinically indicated to the lowest dose that maintains a stable platelet
count 20,000/(micro)L above baseline while maximizing tolerability. Response will be assessed
at 3-4 months. Platelet response is defined as platelet count increases to 20,000/L above
baseline at three months. or stable platelet counts with transfusion independence for a
minimum of 8 weeks. Erythroid response for subjects with a pretreatment hemoglobin of less
than 9 g/dL will be defined as an increase in hemoglobin by greater than or equal to 1.5g/dL
without packed red blood cell (PRBC) transfusion support, or a reduction in the units of
transfusions by an absolute number of at least 4 PRBC transfusions for eight consecutive
weeks compared with the pretreatment transfusion number in the previous 8 weeks. Neutrophil
response will be defined in those with a pretreatment absolute neutrophil count (ANC) of less
than 0.5 times 10(9)/L as at least a 100 percent increase or an absolute increase greater
than 0.5 times 10(9)/L. Subjects with response at 3-4 months may continue study medication
(extended access) until they meet an off study criteria. The primary objective is to assess
the safety and efficacy of the oral thrombopoietin receptor agonist (TPO-R agonist)
eltrombopag in aplastic anemia patients with immunosuppressive-therapy refractory
thrombocytopenia. Secondary objectives include the analysis of the incidence and severity of
bleeding episodes, and the impact on quality of life.
treated with immunosuppressive drug regimens or allogeneic stem cell transplantation.
However, 20-40% of patients without transplant options do not respond to immunosuppressive
therapies, and have persistent severe cytopenias, requiring regular platelet transfusions,
which are expensive and inconvenient, and are a risk for further serious bleeding
complications.
Thrombopoietin (TPO) is the principal endogenous regulator of platelet production and also
stimulates hematopoietic stem and progenitor cells. A small molecule oral TPO-agonist,
eltrombopag has been shown to increase platelets in healthy subjects and in patients with
immune thrombocytopenic purpura (ITP), and received FDA approval in 2008 for the treatment of
thrombocytopenia in ITP. This Phase 2, non-randomized pilot study of eltrombopag in aplastic
anemia patients with immunosuppressive therapy refractory thrombocytopenia will test the
safety and potential efficacy of eltrombopag treatment patients with refractory
thrombocytopenia following immunosuppression for aplastic anemia.
Subjects will initiate study medication at an oral dose of 50 mg/day, which will be increased
up to 150 mg/day as clinically indicated to the lowest dose that maintains a stable platelet
count 20,000/(micro)L above baseline while maximizing tolerability. Response will be assessed
at 3-4 months. Platelet response is defined as platelet count increases to 20,000/L above
baseline at three months. or stable platelet counts with transfusion independence for a
minimum of 8 weeks. Erythroid response for subjects with a pretreatment hemoglobin of less
than 9 g/dL will be defined as an increase in hemoglobin by greater than or equal to 1.5g/dL
without packed red blood cell (PRBC) transfusion support, or a reduction in the units of
transfusions by an absolute number of at least 4 PRBC transfusions for eight consecutive
weeks compared with the pretreatment transfusion number in the previous 8 weeks. Neutrophil
response will be defined in those with a pretreatment absolute neutrophil count (ANC) of less
than 0.5 times 10(9)/L as at least a 100 percent increase or an absolute increase greater
than 0.5 times 10(9)/L. Subjects with response at 3-4 months may continue study medication
(extended access) until they meet an off study criteria. The primary objective is to assess
the safety and efficacy of the oral thrombopoietin receptor agonist (TPO-R agonist)
eltrombopag in aplastic anemia patients with immunosuppressive-therapy refractory
thrombocytopenia. Secondary objectives include the analysis of the incidence and severity of
bleeding episodes, and the impact on quality of life.
Severe aplastic anemia (SAA) is a life-threatening blood disease which can be effectively
treated with immunosuppressive drug regimens or allogeneic stem cell transplantation.
However, 20-40% of patients without transplant options do not respond to immunosuppressive
therapies, and have persistent severe thrombocytopenia. Even patients that respond to
immunosuppressive therapies with an improvement in their life-threatening neutropenia
sometimes have persistent thrombocytopenia. Both groups of patients (i.e. nonresponders to
immunosuppressive therapy and responders with persistent thrombocytopenia) require regular
platelet transfusions, which are expensive and inconvenient, and are a risk for further
serious bleeding complications.
Thrombopoietin (TPO) is the principal endogenous regulator of platelet production. On binding
to the megakaryocyte progenitor TPO receptor, TPO initiates a number of signal transduction
events to increase the production of mature megakaryocytes and platelets. Thrombopoietin also
has stimulatory effects on more primitive multilineage progenitors and stem cells in vitro
and in animal models. A 2nd generation small molecule TPO-agonist, eltrombopag (Promacta )
has been shown to increase platelets in healthy subjects and in thrombocytopenic patients
with chronic immune thrombocytopenic purpura (ITP) and hepatitis C virus (HCV) infection.
Eltrombopag is administered orally and has been well-tolerated in clinical trials. Unlike
recombinant TPO, it has not been found to induce autoantibodies. Eltrombopag received FDA
accelerated approval on Nov 20, 2008 for the treatment of thrombocytopenia in patients with
chronic immune (idiopathic) thrombocytopenic purpura who have had an insufficient response to
corticosteroids, immunoglobulins, or splenectomy.
Because a paucity of megakaryocytes and decreased platelet production is responsible for
thrombocytopenia in aplastic anemia patients, we now propose this Phase 2, non-randomized
pilot study of eltrombopag in aplastic anemia patients with immunosuppressive therapy
refractory thrombocytopenia.
Subjects will initiate study medication at an oral dose of 50 mg/day (25 mg/day for East
Asians), which will be increased or decreased as clinically indicated to the lowest dose that
maintains a stable platelet count greater than or equal to 20,000/microL above baseline while
maximizing tolerability. Platelet treatment response is defined as platelet count increases
to 20,000/microL above baseline at three months, or stable platelet counts with transfusion
independence for a minimum of 8 weeks. Erythroid response for subjects with a pretreatment
hemoglobin of less than 9 g/dL will be defined as an increase in hemoglobin by greater than
or equal to 1.5g/dL without packed red blood cell (PRBC) transfusion support, or a reduction
in the units of transfusions by an absolute number of at least 4 PRBC transfusions for eight
consecutive weeks compared with the pretreatment transfusion number in the previous 8 weeks.
Neutrophil response will be defined in those with a pretreatment absolute neutrophil count
(ANC) of less than 0.5 times 10(9)/L as at least a 100 percent increase or an absolute
increase greater than 0.5 times 10(9)/L. Subjects with a platelet, erythroid, and/or
neutrophil response at 12 weeks may continue study medication (extended access) until they
meet an off study criteria. Subjects with platelet, erythroid, or neutrophil response at 12
weeks may continue study medication for an additional 4 weeks (to ensure eligibility) prior
to being consented for entry into the extended access part of the trial. Patients may remain
on the extended access trial until they met an off study criteria.
The primary objective is to assess the safety and efficacy of the oral thrombopoietin
receptor agonist (TPO-R agonist) eltrombopag in aplastic anemia patients with
immunosuppressive-therapy refractory thrombocytopenia.
Secondary objectives include the analysis of the incidence and severity of bleeding episodes,
and the impact on quality of life.
The primary endpoint will be the portion of drug responders as defined by changes in the
platelet count and/or platelet transfusion requirements, hemoglobin levels, number of red
blood cell transfusions, or neutrophil counts as measured by International Working Group
criteria and the toxicity profile as measured using the CTCAE criteria. Platelet treatment
response is defined as platelet count increases to 20,000/microL above baseline at three
months, or stable platelet counts with transfusion independence for a minimum of 8 weeks.
Erythroid response for subjects with a pretreatment hemoglobin of less than 9g/dL will be
defined as an increase in hemoglobin by greater than or equal to 1.5g/dL or a reduction in
the units of PRBC transfusions by at least 50% during the eight consecutive weeks prior to
response assessment compared with the pretreatment transfusion number in the previous 8
weeks. Neutrophil response will be defined in those with pretreatment absolute neutrophil
count (ANC) of less than 0.5 times 10(9)/L as at least a 100 percent increase in ANC, or an
ANC increase greater than 0.5 times 10(9)/L.
Secondary endpoints will include incidence of bleeding; changes in serum thrombopoietin level
(as measured by enzyme-linked immunosorbent assay, R&D Systems), and health related quality
of life (as measured by the Medical Outcomes Study 36-Item Short Form General Health Survey,
version 2 [SF36v2J]; Quality-Metric) measured at 12 weeks.
treated with immunosuppressive drug regimens or allogeneic stem cell transplantation.
However, 20-40% of patients without transplant options do not respond to immunosuppressive
therapies, and have persistent severe thrombocytopenia. Even patients that respond to
immunosuppressive therapies with an improvement in their life-threatening neutropenia
sometimes have persistent thrombocytopenia. Both groups of patients (i.e. nonresponders to
immunosuppressive therapy and responders with persistent thrombocytopenia) require regular
platelet transfusions, which are expensive and inconvenient, and are a risk for further
serious bleeding complications.
Thrombopoietin (TPO) is the principal endogenous regulator of platelet production. On binding
to the megakaryocyte progenitor TPO receptor, TPO initiates a number of signal transduction
events to increase the production of mature megakaryocytes and platelets. Thrombopoietin also
has stimulatory effects on more primitive multilineage progenitors and stem cells in vitro
and in animal models. A 2nd generation small molecule TPO-agonist, eltrombopag (Promacta )
has been shown to increase platelets in healthy subjects and in thrombocytopenic patients
with chronic immune thrombocytopenic purpura (ITP) and hepatitis C virus (HCV) infection.
Eltrombopag is administered orally and has been well-tolerated in clinical trials. Unlike
recombinant TPO, it has not been found to induce autoantibodies. Eltrombopag received FDA
accelerated approval on Nov 20, 2008 for the treatment of thrombocytopenia in patients with
chronic immune (idiopathic) thrombocytopenic purpura who have had an insufficient response to
corticosteroids, immunoglobulins, or splenectomy.
Because a paucity of megakaryocytes and decreased platelet production is responsible for
thrombocytopenia in aplastic anemia patients, we now propose this Phase 2, non-randomized
pilot study of eltrombopag in aplastic anemia patients with immunosuppressive therapy
refractory thrombocytopenia.
Subjects will initiate study medication at an oral dose of 50 mg/day (25 mg/day for East
Asians), which will be increased or decreased as clinically indicated to the lowest dose that
maintains a stable platelet count greater than or equal to 20,000/microL above baseline while
maximizing tolerability. Platelet treatment response is defined as platelet count increases
to 20,000/microL above baseline at three months, or stable platelet counts with transfusion
independence for a minimum of 8 weeks. Erythroid response for subjects with a pretreatment
hemoglobin of less than 9 g/dL will be defined as an increase in hemoglobin by greater than
or equal to 1.5g/dL without packed red blood cell (PRBC) transfusion support, or a reduction
in the units of transfusions by an absolute number of at least 4 PRBC transfusions for eight
consecutive weeks compared with the pretreatment transfusion number in the previous 8 weeks.
Neutrophil response will be defined in those with a pretreatment absolute neutrophil count
(ANC) of less than 0.5 times 10(9)/L as at least a 100 percent increase or an absolute
increase greater than 0.5 times 10(9)/L. Subjects with a platelet, erythroid, and/or
neutrophil response at 12 weeks may continue study medication (extended access) until they
meet an off study criteria. Subjects with platelet, erythroid, or neutrophil response at 12
weeks may continue study medication for an additional 4 weeks (to ensure eligibility) prior
to being consented for entry into the extended access part of the trial. Patients may remain
on the extended access trial until they met an off study criteria.
The primary objective is to assess the safety and efficacy of the oral thrombopoietin
receptor agonist (TPO-R agonist) eltrombopag in aplastic anemia patients with
immunosuppressive-therapy refractory thrombocytopenia.
Secondary objectives include the analysis of the incidence and severity of bleeding episodes,
and the impact on quality of life.
The primary endpoint will be the portion of drug responders as defined by changes in the
platelet count and/or platelet transfusion requirements, hemoglobin levels, number of red
blood cell transfusions, or neutrophil counts as measured by International Working Group
criteria and the toxicity profile as measured using the CTCAE criteria. Platelet treatment
response is defined as platelet count increases to 20,000/microL above baseline at three
months, or stable platelet counts with transfusion independence for a minimum of 8 weeks.
Erythroid response for subjects with a pretreatment hemoglobin of less than 9g/dL will be
defined as an increase in hemoglobin by greater than or equal to 1.5g/dL or a reduction in
the units of PRBC transfusions by at least 50% during the eight consecutive weeks prior to
response assessment compared with the pretreatment transfusion number in the previous 8
weeks. Neutrophil response will be defined in those with pretreatment absolute neutrophil
count (ANC) of less than 0.5 times 10(9)/L as at least a 100 percent increase in ANC, or an
ANC increase greater than 0.5 times 10(9)/L.
Secondary endpoints will include incidence of bleeding; changes in serum thrombopoietin level
(as measured by enzyme-linked immunosorbent assay, R&D Systems), and health related quality
of life (as measured by the Medical Outcomes Study 36-Item Short Form General Health Survey,
version 2 [SF36v2J]; Quality-Metric) measured at 12 weeks.
- INCLUSION CRITERIA:
1. Diagnosis of aplastic anemia, with refractory thrombocytopenia following at least
one treatment course of horse or rabbit ATG/cyclosporine.
2. Platelet count less than or equal to 30,000/microL
3. Age greater than or equal to 12 years old
EXCLUSION CRITERIA:
1. Diagnosis of Fanconi anemia
2. Infection not adequately responding to appropriate therapy
3. Patients with a PNH clone size in neutrophils of greater than or equal to 50%
4. HIV positivity
5. Creatinine > 2.5
6. Bilirubin > 2.0
7. SGOT or SGPT > 5 times the upper limit of normal
8. Hypersensitivity to eltrombopag or its components
9. Female subjects who are nursing or pregnant or are unwilling to take oral
contraceptives or refrain from pregnancy if of childbearing potential
10. History of malignancy other than localized tumors diagnosed more than one year
previously and treated surgically with curative intent (for instance squamous cell or
other skin cancers, stage 1 breast cancer, cervical carcinoma in situ, etc)
11. Unable to understand the investigational nature of the study or give informed consent
12. History of congestive heart failure arrhythmia requiring chronic treatment, arterial
or venous thrombosis (not excluding line thrombosis) within the last 1 year, or
myocardial infarction within 3 months before enrollment
13. ECOG Performance Status of 3 or greater
14. Treatment with horse or rabbit ATG or Campath within 6 months of study entry.
Concurrent stable treatment with cyclosporine or G-CSF is permitted.
We found this trial at
1
site
9000 Rockville Pike
Bethesda, Maryland 20892
Bethesda, Maryland 20892
Click here to add this to my saved trials
